FDA Expands Marstacimab Indication in Hemophilia A and B - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Expands Marstacimab Indication in Hemophilia A and B

Phase 3 BASIS and BASIS KIDS data supported the expanded indication across pediatric and inhibitor-pretreated populations.

  • By

  • Kathryn Wighton

  • June 8, 2026

  • 3 min

Share

Original Source(s)

FDA Expands Marstacimab Indication in Hemophilia A and B

  • by Kathryn Wighton

  • June 8, 2026

Related Content

Evaluation of the Square Eyes Model as a Screening Tool for Identifying Digital Technologies in Wearable Camera Images Among Children: Laboratory Study

Educators weigh how to use AI without losing critical thinking

Greater productivity is not necessarily indicative of greater knowledge.

Error in Figure

  • September 14, 2026